Skip to main content
Erschienen in: Annals of Surgical Oncology 13/2014

01.12.2014 | Hepatobiliary Tumors

CT-Guided High-Dose-Rate Brachytherapy of Liver Tumours Does Not Impair Hepatic Function and Shows High Overall Safety and Favourable Survival Rates

verfasst von: Georg Brinkhaus, MD, Johan Friso Lock, MD, Maciej Malinowski, MD, PhD, Timm Denecke, MD, PhD, Peter Neuhaus, MD, Bernd Hamm, MD, Bernhard Gebauer, MD, Martin Stockmann, MD, PhD

Erschienen in: Annals of Surgical Oncology | Ausgabe 13/2014

Einloggen, um Zugang zu erhalten

Abstract

Background or Purpose

Computed tomography-guided high-dose-rate brachytherapy (CT-HDRBT) is an emerging therapeutic option for irresectable liver tumours. However, its potentially negative effect on liver function has not yet been investigated. The aim of this study was to evaluate CT-HDRBT for potential liver damage and functional impairment by means of quantitative liver function tests, patient safety, and survival.

Methods

Sixty-nine patients receiving hepatic CT-HDRBT were investigated in a prospective study. The liver function was determined before and after intervention, and 6 and 12 weeks later. The study visits included liver function assessment by conventional biochemical parameters, the liver function capacity test based on 13C-Methacetin (MA) kinetics in µg/kg/hr (LiMAx test), and the indocyanine green plasma disappearance rate test. Tumour progression was re-staged by magnetic resonance imaging (MRI) twice. The 2-year-survival was analysed.

Results

A significant alteration of biochemical liver parameters was observed for liver enzymes and bilirubin directly after intervention, all biochemical parameters had normalised at the 6-week follow-up. There were no changes in LiMAx test values after the intervention, showing no effect on metabolic liver function capacity. In approximately two-thirds of the patients, MRI re-staging revealed a significant tumour response, and no local tumour recurrence occurred. No patient developed a radiation-induced liver disease.

Conclusion

CT-HDRBT for local tumour treatment has little impact on total liver function capacity by high patient safety and encouraging survival rates. Thus, it should be an important option in treating patients without a surgical alternative, especially when liver function is impaired due to previous surgery or chronic liver disease.
Literatur
1.
Zurück zum Zitat Ricke J, Wust P. Computed tomography-guided brachytherapy for liver cancer. Semin Radiat Oncol. 2011;21:287–93.PubMedCrossRef Ricke J, Wust P. Computed tomography-guided brachytherapy for liver cancer. Semin Radiat Oncol. 2011;21:287–93.PubMedCrossRef
2.
Zurück zum Zitat Mohnike K, Wieners G, Schwartz F, et al. Computed tomography-guided high-dose-rate brachytherapy in hepatocellular carcinoma: safety, efficacy, and effect on survival. Int J Radiat Oncol Biol Phys. 2010;78:172–9.PubMedCrossRef Mohnike K, Wieners G, Schwartz F, et al. Computed tomography-guided high-dose-rate brachytherapy in hepatocellular carcinoma: safety, efficacy, and effect on survival. Int J Radiat Oncol Biol Phys. 2010;78:172–9.PubMedCrossRef
3.
Zurück zum Zitat Denecke T, Lopez Hanninen E. Brachytherapy of liver metastases. Recent Results Cancer Res. 2008;177:95–104.PubMedCrossRef Denecke T, Lopez Hanninen E. Brachytherapy of liver metastases. Recent Results Cancer Res. 2008;177:95–104.PubMedCrossRef
4.
Zurück zum Zitat Tselis N, Chatzikonstantinou G, Kolotas C, et al. Hypofractionated accelerated computed tomography-guided interstitial high-dose-rate brachytherapy for liver malignancies. Brachytherapy. 2012;11:507–14.PubMedCrossRef Tselis N, Chatzikonstantinou G, Kolotas C, et al. Hypofractionated accelerated computed tomography-guided interstitial high-dose-rate brachytherapy for liver malignancies. Brachytherapy. 2012;11:507–14.PubMedCrossRef
5.
Zurück zum Zitat Tselis N, Chatzikonstantinou G, Kolotas C, et al. Computed tomography-guided interstitial high dose rate brachytherapy for central located liver tumours: a single institution study. Eur Radiol. 2013;23:2264–70.PubMedCrossRef Tselis N, Chatzikonstantinou G, Kolotas C, et al. Computed tomography-guided interstitial high dose rate brachytherapy for central located liver tumours: a single institution study. Eur Radiol. 2013;23:2264–70.PubMedCrossRef
6.
Zurück zum Zitat Seidensticker M, Seidensticker R, Mohnike K, et al. Quantitative in vivo assessment of radiation injury of the liver using Gd-EOB-DTPA enhanced MRI: tolerance dose of small liver volumes. Radiat Oncol. 2011;6:40.PubMedCentralPubMedCrossRef Seidensticker M, Seidensticker R, Mohnike K, et al. Quantitative in vivo assessment of radiation injury of the liver using Gd-EOB-DTPA enhanced MRI: tolerance dose of small liver volumes. Radiat Oncol. 2011;6:40.PubMedCentralPubMedCrossRef
7.
Zurück zum Zitat Dawson LA, Normolle D, Balter JM, et al. Analysis of radiation-induced liver disease using the Lyman NTCP model. Int J Radiat Oncol Biol Phys. 2002;53:810–21.PubMedCrossRef Dawson LA, Normolle D, Balter JM, et al. Analysis of radiation-induced liver disease using the Lyman NTCP model. Int J Radiat Oncol Biol Phys. 2002;53:810–21.PubMedCrossRef
8.
Zurück zum Zitat Emami B, Lyman J, Brown A, et al. Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys. 1991;21:109–22.PubMedCrossRef Emami B, Lyman J, Brown A, et al. Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys. 1991;21:109–22.PubMedCrossRef
9.
Zurück zum Zitat Marks LB, Yorke ED, Jackson A, et al. Use of normal tissue complication probability models in the clinic. Int J Radiat Oncol Biol Phys. 2010;76:10–9.CrossRef Marks LB, Yorke ED, Jackson A, et al. Use of normal tissue complication probability models in the clinic. Int J Radiat Oncol Biol Phys. 2010;76:10–9.CrossRef
10.
Zurück zum Zitat Stockmann M, Lock JF, Malinowski M, et al. The LiMAx test: a new liver function test for predicting postoperative outcome in liver surgery. HPB. 2010;12:139–46.PubMedCentralPubMedCrossRef Stockmann M, Lock JF, Malinowski M, et al. The LiMAx test: a new liver function test for predicting postoperative outcome in liver surgery. HPB. 2010;12:139–46.PubMedCentralPubMedCrossRef
11.
Zurück zum Zitat Rühl R, Lüdemann L, Czarnecka A, et. al. Radiobiological restrictions and tolerance doses of repeated single-fraction hdr-irradiation of intersecting small liver volumes for recurrent hepatic metastases. Radiat Oncol. 2010;5:44PubMedCentralPubMedCrossRef Rühl R, Lüdemann L, Czarnecka A, et. al. Radiobiological restrictions and tolerance doses of repeated single-fraction hdr-irradiation of intersecting small liver volumes for recurrent hepatic metastases. Radiat Oncol. 2010;5:44PubMedCentralPubMedCrossRef
12.
Zurück zum Zitat Ricke J, Wust P, Wieners G, et al. Liver malignancies: CT-guided interstitial brachytherapy in patients with unfavorable lesions for thermal ablation. J Vasc Interv Radiol. 2004;15:1279–86.PubMedCrossRef Ricke J, Wust P, Wieners G, et al. Liver malignancies: CT-guided interstitial brachytherapy in patients with unfavorable lesions for thermal ablation. J Vasc Interv Radiol. 2004;15:1279–86.PubMedCrossRef
13.
Zurück zum Zitat Wieners G, Pech M, Rudzinska M, et. al. CT-guided interstitial brachytherapy in the local treatment of extrahepatic, extrapulmonary secondary malignancies. Eur Radiol. 2006;16:2586–2593.PubMedCrossRef Wieners G, Pech M, Rudzinska M, et. al. CT-guided interstitial brachytherapy in the local treatment of extrahepatic, extrapulmonary secondary malignancies. Eur Radiol. 2006;16:2586–2593.PubMedCrossRef
14.
Zurück zum Zitat Ricke J, Mohnike K, Pech M, et. al. Local response and impact on survival after local ablation of liver metastases from colorectal carcinoma by computed tomography-guided high-dose-rate brachytherapy. Int J Radiat Oncol Biol Phys. 2010;78:479–485PubMedCrossRef Ricke J, Mohnike K, Pech M, et. al. Local response and impact on survival after local ablation of liver metastases from colorectal carcinoma by computed tomography-guided high-dose-rate brachytherapy. Int J Radiat Oncol Biol Phys. 2010;78:479–485PubMedCrossRef
15.
Zurück zum Zitat Schnapauff D, Denecke T, Grieser C, et al. Computed tomography-guided interstitial HDR brachytherapy (CT-HDRBT) of the liver in patients with irresectable intrahepatic cholangiocarcinoma. Cardiovasc Intervent Radiol. 2012;35:581–7.PubMedCrossRef Schnapauff D, Denecke T, Grieser C, et al. Computed tomography-guided interstitial HDR brachytherapy (CT-HDRBT) of the liver in patients with irresectable intrahepatic cholangiocarcinoma. Cardiovasc Intervent Radiol. 2012;35:581–7.PubMedCrossRef
16.
Zurück zum Zitat Collettini F, Poellinger A, Schnapauff D, et al. CT-guided high-dose-rate brachytherapy of metachronous ovarian cancer metastasis to the liver: initial experience. Anticancer Res. 2011;31:2597–602.PubMed Collettini F, Poellinger A, Schnapauff D, et al. CT-guided high-dose-rate brachytherapy of metachronous ovarian cancer metastasis to the liver: initial experience. Anticancer Res. 2011;31:2597–602.PubMed
17.
Zurück zum Zitat Ruhl R, Seidensticker M, Peters N, et al. Hepatocellular carcinoma and liver cirrhosis: assessment of the liver function after Yttrium-90 radioembolization with resin microspheres or after CT-guided high-dose-rate brachytherapy. Dig Dis. 2009;27:189–99.PubMedCrossRef Ruhl R, Seidensticker M, Peters N, et al. Hepatocellular carcinoma and liver cirrhosis: assessment of the liver function after Yttrium-90 radioembolization with resin microspheres or after CT-guided high-dose-rate brachytherapy. Dig Dis. 2009;27:189–99.PubMedCrossRef
18.
Zurück zum Zitat Stockmann M, Lock JF, Riecke B, et. al. Prediction of postoperative outcome after hepatectomy with a new bedside test for maximal liver function capacity. Ann Surg. 2009;250:119–25.PubMedCrossRef Stockmann M, Lock JF, Riecke B, et. al. Prediction of postoperative outcome after hepatectomy with a new bedside test for maximal liver function capacity. Ann Surg. 2009;250:119–25.PubMedCrossRef
19.
Zurück zum Zitat Stockmann M, Malinowski M, Lock JF, Seehofer D, Neuhaus P. Factors influencing the indocyanine green (ICG) test: additional impact of acute cholestasis. Hepatogastroenterology. 2009;56:734–8PubMed Stockmann M, Malinowski M, Lock JF, Seehofer D, Neuhaus P. Factors influencing the indocyanine green (ICG) test: additional impact of acute cholestasis. Hepatogastroenterology. 2009;56:734–8PubMed
20.
Zurück zum Zitat Lock J, Malinowski M, Seehofer D, et al. Function and volume recovery after partial hepatectomy: influence of preoperative liver function, residual liver volume, and obesity. Langenbecks Arch Surg. 2012;397:1297–304.PubMedCrossRef Lock J, Malinowski M, Seehofer D, et al. Function and volume recovery after partial hepatectomy: influence of preoperative liver function, residual liver volume, and obesity. Langenbecks Arch Surg. 2012;397:1297–304.PubMedCrossRef
21.
Zurück zum Zitat Ricke J, Wust P, Wieners G, et al. Liver malignancies: CT-guided interstitial brachytherapy in patients with unfavorable lesions for thermal ablation. J Vasc Interv Radiol. 2004;15(11):1279–86.PubMedCrossRef Ricke J, Wust P, Wieners G, et al. Liver malignancies: CT-guided interstitial brachytherapy in patients with unfavorable lesions for thermal ablation. J Vasc Interv Radiol. 2004;15(11):1279–86.PubMedCrossRef
22.
Zurück zum Zitat Wieners G, Mohnike K, Peters N, et al. Treatment of hepatic metastases of breast cancer with CT-guided interstitial brachytherapy—a phase II-study. Radiother Oncol. 2011;100:314–9.PubMedCrossRef Wieners G, Mohnike K, Peters N, et al. Treatment of hepatic metastases of breast cancer with CT-guided interstitial brachytherapy—a phase II-study. Radiother Oncol. 2011;100:314–9.PubMedCrossRef
23.
Zurück zum Zitat Llovet JM, Bruix J. Novel advancements in the management of hepatocellular carcinoma in 2008. J Hepatol. 2008;48 Suppl 1:20–37.CrossRef Llovet JM, Bruix J. Novel advancements in the management of hepatocellular carcinoma in 2008. J Hepatol. 2008;48 Suppl 1:20–37.CrossRef
24.
Zurück zum Zitat Stang A, Fischbach R, Teichmann W, et al. A systematic review on the clinical benefit and role of radiofrequency ablation as treatment of colorectal liver metastases. Eur J Cancer. 2009;45:1748–56.PubMedCrossRef Stang A, Fischbach R, Teichmann W, et al. A systematic review on the clinical benefit and role of radiofrequency ablation as treatment of colorectal liver metastases. Eur J Cancer. 2009;45:1748–56.PubMedCrossRef
25.
Zurück zum Zitat Curley SA. Radiofrequency ablation versus resection for resectable colorectal liver metastases: time for a randomized trial? Ann Surg Oncol. 2008;15:11–3.PubMedCentralPubMedCrossRef Curley SA. Radiofrequency ablation versus resection for resectable colorectal liver metastases: time for a randomized trial? Ann Surg Oncol. 2008;15:11–3.PubMedCentralPubMedCrossRef
Metadaten
Titel
CT-Guided High-Dose-Rate Brachytherapy of Liver Tumours Does Not Impair Hepatic Function and Shows High Overall Safety and Favourable Survival Rates
verfasst von
Georg Brinkhaus, MD
Johan Friso Lock, MD
Maciej Malinowski, MD, PhD
Timm Denecke, MD, PhD
Peter Neuhaus, MD
Bernd Hamm, MD
Bernhard Gebauer, MD
Martin Stockmann, MD, PhD
Publikationsdatum
01.12.2014
Verlag
Springer US
Erschienen in
Annals of Surgical Oncology / Ausgabe 13/2014
Print ISSN: 1068-9265
Elektronische ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-014-3835-y

Weitere Artikel der Ausgabe 13/2014

Annals of Surgical Oncology 13/2014 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.